Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | KMO | O15229 | 2/20 | 0.48 |
| ▸ | PPARG | P37231 | 3/20 | 0.47 |
| ▸ | PPARD | Q03181 | 3/20 | 0.47 |
| ▸ | PPARA | Q07869 | 3/20 | 0.47 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 6/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.44 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.44 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL418013 | 0.87 | KMT2A (0.60) | KMT2AEGFRPPARGPPARDPPARA | |
| SCHEMBL23631602 | 0.84 | KDM4E (0.48) | KMT2AEGFRKMONTSR1FGFR1 | |
| SCHEMBL26684010 | 0.84 | KMO (0.68) | KMOHTR7FGFR1FGFR4 | |
| SCHEMBL21810438 | 0.81 | KDM4E (0.48) | NTSR1HTR7FGFR1FGFR4PRMT5 | |
| SCHEMBL7258387 | 0.81 | KMO (0.57) | KMOHTR7 | |
| SCHEMBL29957878 | 0.80 | KMO (0.72) | KMT2AKMOPPARGPPARDPPARA | |
| SCHEMBL1576364 | 0.80 | KMO (0.72) | KMT2AKMOPPARGPPARDPPARA | |
| SCHEMBL2869168 | 0.80 | KMT2A (0.60) | KMT2AEGFRKMOPPARGPPARD | |
| SCHEMBL16156155 | 0.80 | KMT2A (0.60) | KMT2AKMOPPARGPPARDPPARA | |
| SCHEMBL27898692 | 0.80 | KMT2A (0.60) | KMT2AKMOPPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374007-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374007-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | RARA, RARG, RARB | KMT2A 1097/4885EGFR 815/4885KMO 1891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.